26 May 2013
Keywords: rigel, completes, ph, trail, ra, candidate, pharmaceuticals
Article | 11 April 2005
Rigel Pharmaceuticals of the USA says that results from a recently-completed Phase I clinical study of R406, its oral rheumatoid
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
11 April 2005
24 May 2013
© 2013 thepharmaletter.com